Greenland Mines CFO Acquires 1.4 Million Shares in Open-Market Transactions

Greenland Mines Ltd. (NASDAQ: GRML) disclosed in a Form 4 filing that Chief Financial Officer Jeff LeBlanc purchased 1.4 million shares of the company's common stock in open-market transactions. According to the filing, LeBlanc acquired the shares at a price of $0.1752 per share, increasing his direct beneficial ownership to 4,820,342 shares. The filing states that LeBlanc purchased 626,472 shares on July 16, 2026, and an additional 773,528 shares on July 17, 2026. The transactions were reported in a filing with the U.S. Securities and Exchange Commission on July 17.

This insider purchase is significant because it demonstrates confidence from a key executive in the company's future prospects. Greenland Mines operates two divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho's KLTO‑202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

The insider purchase comes at a time when the company is advancing its critical minerals projects, which are increasingly important for global supply chains. Rare earth elements like neodymium and praseodymium are essential for permanent magnets used in electric vehicles, wind turbines, and other clean energy technologies. The Skaergaard Project is one of the world's largest undeveloped palladium and gold deposits, while the Sarfartoq project, once closed, would add significant rare earth resources.

In the biotech division, Klotho's KLTO‑202 is being developed for ALS, a neurodegenerative disease with no cure. This dual focus on critical minerals and biotech provides diversification but also requires significant capital. LeBlanc's purchase suggests that management believes the current stock price undervalues the company's assets and potential.

For more information, visit the company's newsroom at https://ibn.fm/GRML.